Home Featured Page 201

Featured

Latest

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

Silo Pharma Reports Third Quarter Results and Operating Highlights

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’...

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

MYND Executes LOI to Enter into a Clinical Research Collaboration with...

COMPASS Pathways plc announces financial results and business highlights for the...

Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation...

PTSF84 – A Brief Check-in From Wonderland

1...200201202...296 Page 201 of 296

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

August 2025 Psychedelic Patent Update

Unpacking FDA’s MDMA Rejection Letter and the Road Ahead for Lykos

PharmaTher Announces Positive Research Results for Psilocybin Microneedle Patch

Silo Pharma Reports Third Quarter Results and Operating Highlights

Mydecine’s Chief Medical Officer, Dr. Rakesh Jetly, to Participate at Horizons’...

Numinus to Host Extension of MAPS-Sponsored MDMA-Assisted Therapy for PTSD Trials

Entheon Biomedical Announces Recruitment Underway in EBIQ-101 Clinical Study

Nova Mentis Files Genetic Neuroinflammatory Disease Patent

MYND Executes LOI to Enter into a Clinical Research Collaboration with...

COMPASS Pathways plc announces financial results and business highlights for the...

Mindset Pharma Announces Poster Presentation of Preclinical Data for Benchmarking Next-Generation...

PTSF84 – A Brief Check-in From Wonderland

EDITOR PICKS

Dee Dee Goldpaugh – Embracing Pleasure

Q3’25 Psychedelic Drug Development Pipeline: Bullseye Charts

‘No Prejudice, No Hype’: Florence Butlen-Ducuing on Europe’s Psychedelic Renaissance

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY